|
WO2015036579A1
|
|
Albumin variants
|
|
WO2014096440A2
|
|
Albumin composition for preventing and/or reducing formation of peptide fibrils
|
|
WO2014096257A1
|
|
Freeze-dried cross-linked hyaluronic acid sponge
|
|
CN105452290A
|
|
Albumin variants
|
|
WO2014020130A2
|
|
Albumin composition
|
|
CN104736559A
|
|
Albumin variants
|
|
WO2013030348A1
|
|
Oral formulations containing hyaluronic acid for sustained drug release
|
|
SG10201606161UA
|
|
Albumin Formulation and Use
|
|
AU2012264806A1
|
|
Spray drying of high molecular weight hyaluronic acid
|
|
EP2635598A1
|
|
Albumin variants
|
|
CN106977608A
|
|
Albumin derivant and variant
|
|
CN105567699A
|
|
Albumin variants
|
|
CN102549012A
|
|
Method for purifying albumin
|
|
WO2010128145A1
|
|
Method of controlling o-linked glycosylation of antibodies
|
|
SG172789A1
|
|
Albumin variants and conjugates
|
|
EP2393834A1
|
|
Purification process
|
|
WO2010003797A1
|
|
Hyaluronic acid for corneal wound healing
|
|
WO2009030720A2
|
|
Process for producing a recombinant protein
|
|
EP2604623A2
|
|
Transferrin variants and conjugates
|
|
AU2007219545A1
|
|
Aryl/alkyl vinyl sulfone hyaluronic acid derivatives
|
